Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 21, Issue 4, Pages 159-172
http://dx.doi.org/10.1155/2010/303474
Special Article

Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults

Anita Rachlis,1 Marianne Harris,2 Richard Lalonde,3 Stephen D Shafran,4 Cécile Tremblay,5 Mark A Wainberg,6 and Sharon Walmsley7

1Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
2AIDS Research Program, St Paul’s Hospital, Vancouver, British Columbia, Canada
3Immunodeficiency Service and Division of Infectious Diseases, McGill University Health Centre, Montreal, Quebec, Canada
4Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
5Department of Microbiology and Immunology, Centre Hospitalier de l’Université de Montréal, Canada
6McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
7Division of Infectious Diseases, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada

Copyright © 2010 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Anita Rachlis, Marianne Harris, Richard Lalonde, et al., “Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults,” Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 21, no. 4, pp. 159-172, 2010. https://doi.org/10.1155/2010/303474.